It is commonly seen in anatomical regions such as the uterus, deep extremities, blood vessels, retroperitoneum, and superficial dermis [56]. In a study conducted by Hill et al., it was shown that 14% of leiomyosarcoma patients had K-RAS mutation, and K-RAS mutation carriers had lower overall survival rates than others [57]. Here, KRAS is linked to leiomyosarcoma.